個人化醫療市場分析及預測（至2035年）：按類型、產品、服務、技術、應用、最終用戶、組件、設備、流程和解決方案分類

預計到2034年，個人化醫療市場規模將從2024年的5,651億美元成長至1,1,274億美元，年複合成長率約為8.4%。個人化醫療市場涵蓋根據個人基因譜、生活方式和環境量身定做的醫療保健解決方案，從而實現精準治療。該市場利用基因組學、診斷技術和數據分析來最佳化治療效果。對標靶治療的需求不斷成長以及生物技術的進步正在推動市場成長，並促進藥物研發、診斷技術和患者照護策略的創新。

個人化醫療市場正經歷強勁成長，這主要得益於基因組學和生物技術的進步。治療藥物領域成長最為迅猛，這主要得益於標靶治療和生物製藥的普及，它們能夠提供個人化的治療方案；其次是伴隨診斷，它能夠實現精準的患者分層和監測。在治療藥物領域，腫瘤學佔據主導地位，受益於個人化癌症治療，患者預後得到顯著改善。循環系統和神經系統疾病領域的應用也呈現成長勢頭，反映出人們對個人化醫療的日益關注。成長速度第二快的領域是個人化營養和健康，隨著消費者尋求客製化的健康解決方案，該領域持續擴張。營養基因組學和基於微生物組的產品處於領先地位，提供個人化的飲食建議和補充劑。基因檢測服務也不斷發展，能夠深入了解個體的健康風險和易感性。人工智慧和巨量資料分析的融合進一步推動了個人化醫療解決方案的發展，並促進了整個市場的創新和效率提升。

在個人化醫療市場，創新產品的推出和策略定價策略正在塑造市場佔有率的趨勢。各公司正專注於以精準醫療為基礎的治療方法，從而形成由技術進步驅動的競爭格局。對個人化治療方案的需求正在迅速成長，尤其是在腫瘤和罕見疾病領域。這一趨勢促使製藥公司加強研發投入，並培育創新文化。因此，市場正朝著更具針對性和有效性的治療方案轉變，從而改善患者預後並推動產業成長。競爭標竿研究表明，主要參與者正透過先進的基因組學和生物資訊技術加強差異化。監管影響，特別是美國和歐洲的嚴格指導方針，對於確保安全性和有效性以及塑造市場走向至關重要。監管環境在促進創新的同時，也維持高標準。市場分析表明，技術整合和策略聯盟將推動市場強勁成長。數位健康技術和個人化診斷提供了充滿希望的機遇，增強了市場動力。儘管高成本和監管複雜性等挑戰依然存在，但變革醫療保健的解決方案潛力巨大。

主要趨勢和促進因素：

基因組學和生物技術的進步正推動個人化醫療市場強勁成長。人工智慧 (AI) 和機器學習在藥物研發和診斷中的應用是關鍵趨勢。這些技術能夠識別生物標記並制定個人化治療方案，從而改善患者預後。另一個趨勢是，由於慢性病發病率上升以及對更有效治療方法的需求，標靶治療的需求日益成長。個人化醫療提供了一種量身定做的治療方案，可以提高療效並減少副作用。監管機構也發揮重要作用，支持精準醫療舉措，進一步加速市場成長。此外，消費者基因檢測服務的擴展使個人能夠做出明智的健康決策。伴隨診斷的日益普及也促進了這一趨勢，有助於選擇合適的治療方法。數位健康科技與個人化醫療的融合為創新和病人參與創造了新的機遇，為市場的持續擴張奠定了基礎。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 治療
  • 診斷
• 市場規模及預測：依產品分類
  • 藥物基因組學
  • 伴隨診斷
  • 標靶治療藥物
  • 基因檢測套組
• 市場規模及預測：依服務分類
  • 基因測序
  • 分子診斷服務
  • 關於個人化醫療的諮詢
• 市場規模及預測：依技術分類
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 生物資訊學
  • 基因編輯
• 市場規模及預測：依應用領域分類
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 感染疾病
  • 呼吸系統疾病
• 市場規模及預測：依最終用戶分類
  • 醫院
  • 診所
  • 學術研究機構
  • 製藥公司
• 市場規模及預測：依組件分類
  • 軟體
  • 硬體
  • 服務
• 市場規模及預測：依設備分類
  • 穿戴式裝置
  • 即時檢測設備
  • 檢測設備
• 市場規模及預測：依製程分類
  • 生物標記發現
  • 藥物研發
  • 臨床試驗
• 市場規模及預測：按解決方案分類
  • 整合平台
  • 獨立解決方案
  • 客製化解決方案

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 其他亞太地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章：公司簡介

• Illumina
• Qiagen
• Myriad Genetics
• Genomic Health
• Natera
• Foundation Medicine
• Adaptive Biotechnologies
• Guardant Health
• Invitae
• Personalis
• Care Dx
• Blueprint Medicines
• Blueprint Genetics
• Grail
• Freenome
• Sema4
• Tempus
• Caris Life Sciences
• Neo Genomics
• Syapse

第9章：關於我們

Personalized Medicine Market is anticipated to expand from $565.1 billion in 2024 to $1,127.4 billion by 2034, growing at a CAGR of approximately 8.4%. The Personalized Medicine Market encompasses healthcare solutions tailored to individual genetic profiles, lifestyle, and environment, enabling precise medical treatment. This market leverages genomics, diagnostics, and data analytics to optimize therapeutic outcomes. Rising demand for targeted therapies and advancements in biotechnology are propelling growth, fostering innovations in drug development, diagnostics, and patient care strategies.

The Personalized Medicine Market is experiencing robust growth, propelled by advancements in genomics and biotechnology. The therapeutics segment is the top performer, driven by targeted therapies and biologics, which offer tailored treatment options. Companion diagnostics follow closely, enabling precise patient stratification and monitoring. Within the therapeutics segment, oncology holds the leading position, benefiting from personalized cancer treatments that improve patient outcomes. Cardiovascular and neurology applications are also gaining momentum, reflecting an increasing focus on individualized care. The second highest performing segment is the personalized nutrition and wellness sector, which is expanding as consumers seek customized health solutions. Nutrigenomics and microbiome-based products are at the forefront, offering personalized dietary recommendations and supplements. Genetic testing services are also advancing, providing insights into individual health risks and predispositions. The integration of artificial intelligence and big data analytics is further enhancing the personalization of medical solutions, driving innovation and efficiency across the market.

Within the Personalized Medicine Market, innovative product launches and strategic pricing strategies are shaping market share dynamics. Companies are focusing on precision-based therapies, creating a competitive landscape driven by technological advancements. The market is witnessing a surge in demand for personalized treatment solutions, particularly in oncology and rare diseases. This trend is encouraging pharmaceutical companies to invest in research and development, fostering a culture of innovation. As a result, the market is experiencing a shift towards more targeted and effective treatment options, enhancing patient outcomes and driving industry growth. Competition benchmarking reveals that key players are intensifying efforts to differentiate through advanced genomics and bioinformatics. Regulatory influences, particularly in the U.S. and Europe, are pivotal in shaping market trajectories, with stringent guidelines ensuring safety and efficacy. The regulatory landscape is fostering innovation while maintaining high standards. Market analysis indicates a robust growth trajectory, driven by technological integration and strategic collaborations. The market is poised for expansion, with digital health technologies and personalized diagnostics offering lucrative opportunities. Challenges remain, including high costs and regulatory complexities, yet the potential for transformative healthcare solutions is immense.

Geographical Overview:

The personalized medicine market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in genomic research. The region's focus on precision medicine and patient-centric approaches enhances its market position. Europe follows closely, with strong government support and initiatives promoting personalized healthcare solutions. The region's emphasis on innovative healthcare practices fosters a conducive environment for market expansion. In the Asia Pacific, the market is expanding rapidly, propelled by rising healthcare expenditures and increasing awareness of personalized treatment options. Countries like China and India are emerging as key players, investing heavily in biotechnology and genomics. Latin America and the Middle East & Africa are also gaining traction. Brazil and the UAE are recognizing the potential of personalized medicine in improving healthcare outcomes, thus driving investments and fostering growth in these regions.

Global tariffs and geopolitical tensions are recalibrating the Personalized Medicine Market's dynamics, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are fortifying their biopharmaceutical sectors, investing in local R&D to mitigate reliance on foreign imports. China is accelerating its indigenous biotech capabilities, driven by export restrictions and a desire for self-reliance. Taiwan, pivotal in precision medicine technologies, navigates geopolitical sensitivities while maintaining its innovation edge. The global market, buoyed by advancements in genomics and diagnostics, is robust, yet susceptible to supply chain disruptions and energy price volatility, exacerbated by Middle East conflicts. By 2035, the market's evolution will hinge on strategic regional collaborations and resilience against geopolitical and economic uncertainties.

Key Trends and Drivers:

The personalized medicine market is experiencing robust growth, propelled by advances in genomics and biotechnology. A significant trend is the integration of artificial intelligence and machine learning in drug development and diagnostics. These technologies enable the identification of biomarkers and the customization of treatment plans, enhancing patient outcomes. Another trend is the rising demand for targeted therapies, driven by the increasing prevalence of chronic diseases and the need for more effective treatments. Personalized medicine offers tailored approaches that improve efficacy and reduce adverse effects. Regulatory bodies are also playing a pivotal role by supporting precision medicine initiatives, which further accelerates market growth. Additionally, the expansion of direct-to-consumer genetic testing services is empowering individuals to make informed health decisions. This trend is complemented by the growing availability of companion diagnostics, which facilitate the selection of suitable therapies. The convergence of digital health technologies and personalized medicine is creating new opportunities for innovation and patient engagement, positioning the market for sustained expansion.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Device
• 2.9 Key Market Highlights by Process
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Therapeutics
  • 4.1.2 Diagnostics
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pharmacogenomics
  • 4.2.2 Companion Diagnostics
  • 4.2.3 Targeted Therapeutics
  • 4.2.4 Genetic Testing Kits
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Genomic Sequencing
  • 4.3.2 Molecular Diagnostics Services
  • 4.3.3 Personalized Medicine Consultations
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Next-Generation Sequencing
  • 4.4.2 Polymerase Chain Reaction
  • 4.4.3 Bioinformatics
  • 4.4.4 Gene Editing
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Respiratory Diseases
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Clinics
  • 4.6.3 Academic Research Institutions
  • 4.6.4 Pharmaceutical Companies
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Software
  • 4.7.2 Hardware
  • 4.7.3 Services
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 Wearable Devices
  • 4.8.2 Point-of-Care Devices
  • 4.8.3 Laboratory Instruments
• 4.9 Market Size & Forecast by Process (2020-2035)
  • 4.9.1 Biomarker Discovery
  • 4.9.2 Drug Development
  • 4.9.3 Clinical Trials
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Integrated Platforms
  • 4.10.2 Standalone Solutions
  • 4.10.3 Customized Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Device
    • 5.2.1.9 Process
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Device
    • 5.2.2.9 Process
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Device
    • 5.2.3.9 Process
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Device
    • 5.3.1.9 Process
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Device
    • 5.3.2.9 Process
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Device
    • 5.3.3.9 Process
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Device
    • 5.4.1.9 Process
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Device
    • 5.4.2.9 Process
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Device
    • 5.4.3.9 Process
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Device
    • 5.4.4.9 Process
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Device
    • 5.4.5.9 Process
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Device
    • 5.4.6.9 Process
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Device
    • 5.4.7.9 Process
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Device
    • 5.5.1.9 Process
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Device
    • 5.5.2.9 Process
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Device
    • 5.5.3.9 Process
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Device
    • 5.5.4.9 Process
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Device
    • 5.5.5.9 Process
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Device
    • 5.5.6.9 Process
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Device
    • 5.6.1.9 Process
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Device
    • 5.6.2.9 Process
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Device
    • 5.6.3.9 Process
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Device
    • 5.6.4.9 Process
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Device
    • 5.6.5.9 Process
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Illumina
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Qiagen
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Myriad Genetics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Genomic Health
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Natera
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Foundation Medicine
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Adaptive Biotechnologies
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Guardant Health
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Invitae
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Personalis
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Care Dx
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Blueprint Medicines
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Blueprint Genetics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Grail
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Freenome
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Sema4
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Tempus
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Caris Life Sciences
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Neo Genomics
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Syapse
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us